Pfizer (NYSE:PFE) has reached deep into the heart of Europe for its latest product buy. The company announced that a Polish subsidiary has acquired the rights to Polocard, a low-dose aspirin, from local pharmaceutical concern ZF Polpharma. The terms of the deal were not made public.

Described by Pfizer as a leading over-the-counter treatment in Poland, Polocard is frequently used for the prevention of heart attacks. In the press release announcing the acquisition, the pharmaceutical giant said that Polocard "will enhance our Consumer Healthcare portfolio and overall position in this key market."

The purchase of the treatment is part of a broader attempt by the company to boost its presence through acquisitions. Last week, for example, the company announced it had completed the acquisition of NextWave Pharmaceuticals, a company developing products used to treat attention deficit hyperactivity disorder.

Fool contributor Eric Volkman has no position in Pfizer. Nor does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.